Mohammad Burhan Uddin

TL;DR: This review summarizes recent advances in the roles of PI3K/Akt/mTOR and their targets in the development and progression of a broad spectrum of cutaneous cancers and discusses the current progress in preclinical and clinical studies for the development of PI-Akt-based targeted therapies with nutraceuticals and synthetic small molecule inhibitors.

TL;DR: A novel function of pre‐mRNA m6A is uncovered as a determinant of mutant protein expression in cancer cells heterozygously carrying the TP53 R273H mutation, thus sensitizing cells carrying R 273H to anticancer drugs.

TL;DR: The m6A RNA methylation is the most prevalent internal modification in mammalian mRNAs which plays critical biological roles by regulating vital cellular processes Dysregulations due to aberrant expression of its regulatory proteins are frequently observed in many pathological conditions, particularly in cancer Normal cells undergo malignant transformation via activation or modulation of different oncogenic signaling pathways through complex mechanisms as discussed by the authors.

TL;DR: It is demonstrated that p53-R273H promotes EMT and induced pluripotency of CSCs in cancer cells exposed to doxorubicin, mainly through Zeb1 and β-catenin transcription factors and indicates that restoration of p53 through inhibition of ceramide glycosylation might be an effective treatment approach for targeting cancers heterozygously harboring TP53 missense mutations.

TL;DR: It is concluded that, while advanced technologies have uncovered the contributions of many of RNA modifications in cancer, the underlying mechanisms are still poorly understood and further studies are needed to elucidate the mechanism of how RNA modifications promote cell malignant transformation and generation of cancer stem cells, which will lead to the development of new strategies for cancer prevention and treatment.